医学
化疗
挽救疗法
肿瘤科
淋巴瘤
耐火材料(行星科学)
移植
疾病
CD19
B细胞淋巴瘤
B细胞
嵌合抗原受体
内科学
免疫学
抗原
免疫疗法
癌症
抗体
物理
天体生物学
作者
Mark Roschewski,Dan L. Longo,Wyndham H. Wilson
摘要
Large B-cell lymphoma is a spectrum of aggressive B-cell cancers with broad genetic and clinical heterogeneity.1 First-line chemotherapy cures most patients, but those with relapsed or refractory disease usually die of lymphoma. Salvage chemotherapy followed by autologous stem-cell transplantation (ASCT) is the standard second-line approach to large B-cell lymphoma and cures up to 30 to 40% of eligible patients, but it is restricted to younger, fit patients and is relatively ineffective in chemotherapy-refractory disease.2 Chimeric antigen receptor (CAR) T-cell therapies that target CD19 have advanced the treatment of multiply relapsed large B-cell lymphoma and showed promising rates of durable remission . . .
科研通智能强力驱动
Strongly Powered by AbleSci AI